Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Human GnRH receptor extracellular domain (residues 1-29) peptide conjugated to BSA.|
|Contains||0.05% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay dependent.|
|Flow Cytometry (Flow)||Assay dependent.|
|Immunohistochemistry (Frozen) (IHC (F))||Assay dependent.|
|Western Blot (WB)||Assay dependent.|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
The immunogen corresponds to amino acid sequence 1(MANSASPEQNQHCSAINNSIPLMQGNLPY)29 of the human GnRH receptor extracellular domain.
This gene encodes the receptor for type 1 gonadotropin-releasing hormone. This receptor is a member of the seven-transmembrane, G-protein coupled receptor (GPCR) family. It is expressed on the surface of pituitary gonadotrope cells as well as lymphocytes, breast, ovary, and prostate. Following binding of gonadotropin-releasing hormone, the receptor associates with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Activation of the receptor ultimately causes the release of gonadotropic luteinizing hormone (LH) and follicle stimulating hormone (FSH). Defects in this gene are a cause of hypogonadotropic hypogonadism (HH). Alternative splicing results in multiple transcript variants encoding different isoforms. More than 18 transcription initiation sites in the 5' region and multiple polyA signals in the 3' region have been identified for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Gonadotropin-releasing hormone analogues reduce the proliferation of endometrial stromal cells but not endometriotic cells.
MA1-35383 was used in western blot to compare the ability of gonadotropin-releasing hormone analogues to inhibit the proliferation of endometrial stromal cells and endometriotic stromal cells
|Taniguchi F,Higaki H,Azuma Y,Deura I,Iwabe T,Harada T,Terakawa N||Gynecologic and obstetric investigation (75:9)||2013|
Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha.
MA1-35383 was used in western blot to investigate the mechanism for the induction of cell apoptosis by GnRH-II in human endometrial cancer cell lines
|Wu HM,Cheng JC,Wang HS,Huang HY,MacCalman CD,Leung PC||Cancer research (69:4202)||2009|
Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells.
MA1-35383 was used in immunohistochemistry to study the involvement of type I gonadotropin-releasing hormone receptor in the antiproliferative effects of GnRH-II
|Montagnani Marelli M,Moretti RM,Mai S,Januszkiewicz-Caulier J,Motta M,Limonta P||The Journal of clinical endocrinology and metabolism (94:1761)||2009|
gnRH receptor; gnRH-R; GNRHR; gonadotropin-releasing hormone (type 1) receptor 1; leutinizing hormone releasing horomone receptor; leutinizing-releasing hormone receptor; luliberin receptor; type I GnRH receptor
GNRHR; GNRHR1; GRHR; HH7; LHRHR; LRHR